Labcorp Holdings (N6B) Price & Analysis

9 Followers

N6B Stock Chart & Stats

€252.00

€8.00(3.28%)

At close: Jul 24 4:00 PM EDT

€252.00

€8.00(3.28%)

Day’s Range― - ―

52-Week Range€212.00 - €274.00

Previous CloseN/A

Volume0.00

Average Volume (3M)3.00

Market Cap

€21.98B

Enterprise Value€29.60K

Total Cash (Recent Filing)€141.80M

Total Debt (Recent Filing)€6.77B

Price to Earnings (P/E)25.4

Beta0.14

Next Earnings

Oct 22, 2026

EPS Estimate

4.03

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)12.17

Shares Outstanding82,000,000

10 Day Avg. Volume7

30 Day Avg. Volume3

Financial Highlights & Ratios

PEG Ratio1.28

Price to Book (P/B)2.42

Price to Sales (P/S)1.50

P/FCF Ratio17.31

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€291.22

Price Target Upside15.56% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)15.81

Revenue Forecast (FY)€12.77B

Bulls Say, Bears Say

Bulls Say

Diversified, Scale-driven Business ModelLabcorp's two-segment model (Diagnostics and Drug Development) and global scale provide durable revenue diversification. Clinical testing and CRO services expose the company to multiple secular demand drivers, smoothing cycles and enabling cross-selling and operational leverage over the next several quarters.

Improving Revenue And Margins With Raised GuidanceRecent top-line growth and 70bp operating margin expansion signal improving operating leverage. Management's upward guidance and higher EPS midpoint reflect sustainable operational momentum and stronger profitability assumptions for the coming 2–6 months, supporting durable earnings improvement.

Robust BLS Backlog And Book-to-billAn $8.7B BLS backlog and >1 book-to-bill provide visible near-term revenue for the Drug Development segment. This backlog-driven revenue conversion supports predictable, higher-margin central lab workloads and underpins multi-quarter growth visibility for the CRO business.

Bears Say

High Absolute Leverage Despite Manageable RatiosWhile leverage ratios are within industry norms, the large absolute debt stock limits financial flexibility for opportunistic investments or cushioning during downturns. Elevated interest and principal obligations increase vulnerability to cash-flow timing issues over the medium term.

Free Cash Flow Decline And Sub‑optimal ConversionA meaningful decline in FCF and less-than-1x earnings-to-cash conversion reduce internal funding for capex, M&A, and buybacks. Persistent cash conversion variability heightens reliance on external financing and constrains capital allocation flexibility over the coming quarters.

Regulatory And Payer Reimbursement UncertaintyLegislative and regulatory changes to reimbursement (PAMA/RESULTS Act) and payer dynamics can structurally compress realized prices for diagnostics. This persistent policy risk could reduce revenue per test and margin sustainability absent offsetting price/mix gains.

Labcorp Holdings News

Labcorp price target raised to $338 from $308 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Labcorp (LH) to $338 from $308 and keeps an Overweight...

2d ago

Labcorp price target raised to $306 from $276 at Deutsche Bank

Deutsche Bank raised the firm’s price target on Labcorp (LH) to $306 from $276 and keeps a Hold...

2d ago

Labcorp price target raised to $360 from $320 at BofA

BofA raised the firm’s price target on Labcorp (LH) to $360 from $320 and keeps a Buy rating...

2d ago

Labcorp price target raised to $352 from $338 at Baird

Baird raised the firm’s price target on Labcorp (LH) to $352 from $338 and keeps an Outperform rating...

2d ago

Labcorp price target raised to $320 from $290 at Barclays

Barclays raised the firm’s price target on Labcorp (LH) to $320 from $290 and keeps an Equal Weight...

3d ago

Labcorp raises FY26 adjusted EPS view to $18.10-$18.55 from $17.70-$18.35

Consensus $18.01. Raises FY26 revenue view to $14.71B-$14.83B from $14.65B-$14.8B, consensus $14.71B. The company said, “Labcorp (LH) is...

3d ago

Labcorp reports Q2 adjusted EPS $4.99, consensus $4.77

Reports Q2 revenue $3.73B, consensus $3.71B. “Labcorp (LH) delivered another very strong quarter, with 6% revenue growth, significant...

3d ago

Labcorp launches Marker by Labcorp Genetic Health Panel

Labcorp (LH) announced the launch of Marker by Labcorp Genetic Health Panel, a new offering designed to help...

6d ago

Labcorp awarded $364.7M Defense Health Agency contract

Labcorp (LH) was awarded $364.7M for a single-award, indefinite delivery/indefinite quantity contract utilizing firm-fixed-price task orders to provide...

11d ago

Labcorp to pay $14.5M to resolve False Claims Act allegations

Laboratory Corporation of America has agreed to pay $14.5M to resolve allegations that it violated the False Claims...

18d ago

Labcorp: Guidance Raised, Biopharma Momentum Strengthens, and Price Target Increased to $360 on Higher FY27 EBITDA Multiple

Bank of America Securities analyst Michael Ryskin reiterated a Buy rating on Labcorp Holdings yesterday and set a...

2d ago

Labcorp Earnings Call Highlights Growth, Raised Outlook

Labcorp Holdings Inc. (($LH)) has held its Q2 earnings call. Read on for the main highlights of the...

3d ago

LH Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Labcorp Holdings Inc. (LH) is scheduled to report 2nd quarter earnings on 07/30/2026, before the market opens. Regarding...

5d ago

AI Models Turn More Positive on Labcorp as Guidance and Cash Flow Improve

AI models tracking Labcorp Holdings (LH) have turned more constructive following the company’s latest guidance update, with two...

22d ago

N6B FAQ

What was Labcorp Holdings’s price range in the past 12 months?

Labcorp Holdings lowest stock price was €212.00 and its highest was €274.00 in the past 12 months.

What is Labcorp Holdings’s market cap?

Labcorp Holdings’s market cap is €21.98B.

When is Labcorp Holdings’s upcoming earnings report date?

Labcorp Holdings’s upcoming earnings report date is Oct 22, 2026 which is in 81 days.

How were Labcorp Holdings’s earnings last quarter?

Labcorp Holdings released its earnings results on Jul 30, 2026. The company reported €4.325 earnings per share for the quarter, beating the consensus estimate of €4.142 by €0.183.

Is Labcorp Holdings overvalued?

According to Wall Street analysts Labcorp Holdings’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Labcorp Holdings pay dividends?

Labcorp Holdings does not currently pay dividends.

What is Labcorp Holdings’s EPS estimate?

Labcorp Holdings’s EPS estimate is 4.03.

How many shares outstanding does Labcorp Holdings have?

Labcorp Holdings has 82,000,000 shares outstanding.

What happened to Labcorp Holdings’s price movement after its last earnings report?

Labcorp Holdings reported an EPS of €4.325 in its last earnings report, beating expectations of €4.142. Following the earnings report the stock price went down -8.088%.

Which hedge fund is a major shareholder of Labcorp Holdings?

Currently, no hedge funds are holding shares in DE:N6B

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Labcorp Holdings Stock Smart Score

Outperform

Fundamentals

Return on Equity

0.99%

Trailing 12-Months

Asset Growth

2.62%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Labcorp Holdings

Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.

Labcorp Holdings (N6B) Earnings & Revenues

Historic Earnings Reports

N6B Company Deck

N6B Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call presented a strong operational and financial quarter: revenue growth, margin expansion, double-digit adjusted EPS growth, raised guidance, robust BLS backlog and book-to-bill, and multiple product/partnership launches. Headwinds highlighted were a meaningful quarter-over-quarter drop in free cash flow (timing and capex), a modest ACA-related volume headwind (~30 bps), prior and improving Early Development softness, higher patient-pay mix, and elevated absolute debt with relatively low cash on hand. On balance the positives around revenue, margins, guidance increases, product/market progress, and capital returns materially outweigh the cited challenges.View all DE:N6B earnings summaries

N6B Revenue Breakdown

77.96% Dx

22.21% BLS

-0.16% Intercompany eliminations

N6B Stock 12 Month Forecast

Average Price Target

€291.22

▲(15.56% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"209":"€209","314":"€314","235.25":"€235.3","261.5":"€261.5","287.75":"€287.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":313.61524469,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€313.62</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":291.2210505477778,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€291.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":265.83452874,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€265.83</span>\n  </div></div>","useHTML":true}}],"tickPositions":[209,235.25,261.5,287.75,314],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,250,254.89348036076922,259.78696072153843,264.6804410823077,269.5739214430769,274.46740180384614,279.36088216461536,284.25436252538464,289.14784288615385,294.04132324692307,298.9348036076923,303.82828396846156,308.7217643292308,{"y":313.61524469,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,250,253.17085004213675,256.3417000842735,259.51255012641025,262.683400168547,265.85425021068374,269.0251002528205,272.1959502949573,275.36680033709405,278.5376503792308,281.70850042136755,284.8793504635043,288.05020050564104,{"y":291.2210505477778,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,250,251.2180406723077,252.4360813446154,253.65412201692308,254.87216268923078,256.09020336153844,257.30824403384617,258.52628470615383,259.74432537846155,260.9623660507692,262.18040672307694,263.3984473953846,264.61648806769233,{"y":265.83452874,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":217.659,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":221.616,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":232.111,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":240.047,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":216.24,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":226.778,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":210.863,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":222.799,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":243.315,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":227.36,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":219.383,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":222,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":250,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >